The battle for supremacy in metabolic dysfunction-associated steatohepatitis (MASH) is stepping up a gear, and improvement in liver fibrosis is emerging as the key factor for success.
On that score, Boehringer Ingelheim and Zealand Pharma have just bolstered the best-in-class credentials for their dual glucagon/GLP-1 receptor agonist candidate, survodutide, with updated Phase II data presented at the European Association for the Study of the Liver Congress
Key Takeaways
-
Boehringer’s data have been presented at EASL in Milan, going toe-to-toe with rival data from Eli Lilly and others
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?